ArticleCurrent pharmaceutical design2026
Jiawei Zaoqi Decoction Attenuates Polycystic Ovary Syndrome by Inhibiting AGE-RAGE-Mediated Cell Senescence of Granulosa Cells.
Article in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionPolycystic ovary syndrome (PCOS) is a prevalent endocrine disorder characterized by hormonal imbalances, ovarian dysfunction, and metabolic irregularities. Jiawei Zaoqi Decoction (JWZQD), a Traditional Chinese Medicine (TCM) formulation, has shown potential as a multi-targeted therapeutic intervention for PCOS. However, its underlying mechanisms remain unclear. In this study, we explored the therapeutic effects and molecular mechanisms of JWZQD in managing PCOS.
methodsWe employed a multi-model approach integrating clinical data, animal models, and mechanistic assays. Clinical efficacy was evaluated in a cohort of PCOS patients, while a letrozole-induced rat model combined with a high-fat diet was used to assess reproductive and metabolic outcomes. Network pharmacology, Gene Ontology, KEGG enrichment, and protein-protein interaction analyses were applied to identify key targets and pathways. Granulosa-cell experiments under oxidative stress and insulin stimulation were performed for functional validation.
resultsJWZQD administration significantly decreased serum luteinizing hormone and testosterone levels, improved insulin, and restored estrous cyclicity in PCOS patients and rats. Histology and ultrasound revealed reduced cystic follicles and normalized ovarian stroma. Bioinformatic analyses identified cellular senescence and AGE-RAGE signaling as core pathways, with quercetin and fisetin emerging as critical bioactive compounds. In vitro, quercetin and fisetin suppressed senescence markers (p21, p53, γH2AX) and rescued granulosa- cell proliferative capacity, confirming the network predictions. DISCUSSION: These findings provide mechanistic insight into how JWZQD ameliorates PCOS, highlighting its multi-targeted regulation of endocrine, metabolic, and ovarian functions. Importantly, our results suggest that targeting granulosa-cell senescence may represent a novel therapeutic strategy.
conclusionJWZQD mitigates PCOS by modulating AGE-RAGE-mediated granulosa-cell senescence through its active compounds quercetin and fisetin. This study supports the clinical potential of JWZQD as an alternative or complementary therapy for PCOS.
Indexed as
Identifiers
41832685What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.